Experimental CAR-T immunotherapy produces complete regression of chemotherapy-resistant liver cancer in one child
Now Possible · Friday, 11 September 2026
Why it matters
This is a concrete human demonstration that an engineered immune-cell therapy can produce a durable complete response in a chemotherapy-resistant solid tumor, extending CAR-T’s demonstrated reach beyond the blood cancers where it has been most established. Its practical accessibility is still near the trial stage: the result involved a personalized product made in specialized manufacturing laboratories and has not yet shown reproducible benefit across patients or routine availability.
What happened
A 3-year-old with hepatoblastoma that had stopped responding to chemotherapy received two outpatient infusions of personalized GPC3-targeted CAR-T cells engineered to produce IL-15 and IL-21. Imaging showed complete resolution of metastatic disease after the second infusion, with the response continuing for one year; no dose-limiting toxicity or cytokine release syndrome was reported. The treatment is being evaluated in the first-in-human, phase 1 CARE study, so this is evidence from one patient rather than an established therapy for routine clinical use.
Players & places
- Baylor College of Medicine
- Texas Children's Hospital
- Seattle Children's
- Center for Cell and Gene Therapy